Promising approach for targeting ROBO1 with CAR NK cells to combat ovarian cancer primary tumor cells and organoids

References

• Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet 384(9951), 1376–1388 (2014).
   PubMed Web of Science ®Google Scholar
• Shafabakhsh R, Asemi Z. Quercetin: a natural compound for ovarian cancer treatment. J. Ovarian Res. 12(1), 55 (2019).
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J. Clin. 69(1), 7–34 (2019).
   PubMed Web of Science ®Google Scholar
• Moufarrij S, Dandapani M, Arthofer E et al. Epigenetic therapy for ovarian cancer: promise and progress. Clin. Epigenetics 11(1), 7 (2019).
   PubMed Web of Science ®Google Scholar
• Holmes GP, Negus K, Burridge L et al. Distinct but overlapping expression patterns of two vertebrate slit homologs implies functional roles in CNS development and organogenesis. Mech. Dev. 79(1–2), 57–72 (1998).
   PubMed Web of Science ®Google Scholar
• Yuan W, Zhou L, Chen JH, Wu JY, Rao Y, Ornitz DM. The mouse SLIT family: secreted ligands for ROBO expressed in patterns that suggest a role in morphogenesis and axon guidance. Dev. Biol. 212(2), 290–306 (1999).
   PubMed Web of Science ®Google Scholar
• Latil A, Chene L, Cochant-Priollet B et al. Quantification of expression of netrins, slits and their receptors in human prostate tumors. Int. J. Cancer 103(3), 306–315 (2003).
   PubMed Web of Science ®Google Scholar
• Wang B, Xiao Y, Ding BB et al. Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Cell 4(1), 19–29 (2003).
   PubMed Web of Science ®Google Scholar
• Ballard MS, Hinck L. A roundabout way to cancer. Adv. Cancer Res. 114, 187–235 (2012).
   PubMed Web of Science ®Google Scholar
• Wu MF, Liao CY, Wang LY, Chang JT. The role of Slit-Robo signaling in the regulation of tissue barriers. Tissue Barriers 5(2), e1331155 (2017).
   PubMed Web of Science ®Google Scholar
• Dickinson RE, Fegan KS, Ren X, Hillier SG, Duncan WC. Glucocorticoid regulation of SLIT/ROBO tumour suppressor genes in the ovarian surface epithelium and ovarian cancer cells. PLOS ONE 6(11), e27792 (2011).
   PubMed Web of Science ®Google Scholar
• Jones CA, Nishiya N, London NR et al. Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nat. Cell Biol. 11(11), 1325–1331 (2009).
   PubMed Web of Science ®Google Scholar
• Tessema FA, Darrow JJ. A new approach to treat childhood leukemia: Novartis' CAR-T therapy. J. Law Med. Ethics 45(4), 692–697 (2017).
   PubMed Web of Science ®Google Scholar
• Chou CK, Turtle CJ. Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy. Bone Marrow Transplant. 54(Suppl. 2), 780–784 (2019).
   PubMedGoogle Scholar
• Zhang Y, Wallace DL, De Lara CM et al. In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology 121(2), 258–265 (2007).
   PubMed Web of Science ®Google Scholar
• Lupo KB, Matosevic S. Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy. Cancers (Basel) 11(6), 769 (2019).
   PubMed Web of Science ®Google Scholar
• Liu E, Marin D, Banerjee P et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N. Engl. J. Med. 382(6), 545–553 (2020).
   PubMed Web of Science ®Google Scholar
• Brehm C, Huenecke S, Quaiser A et al. IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study. PLOS ONE 6(11), e27351 (2011).
   PubMed Web of Science ®Google Scholar
• Koehl U, Brehm C, Huenecke S et al. Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front Oncol. 3, 118 (2013).
   PubMedGoogle Scholar
• Chen M, Li Y, Wu Y et al. Anti-tumor activity of expanded PBMC-derived NK Cells by feeder-free protocol in ovarian cancer. Cancers (Basel) 13(22), 5866 (2021).
   PubMed Web of Science ®Google Scholar
• Liu B, Liu ZZ, Zhou ML et al. Development of c-MET-specific chimeric antigen receptor-engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells. Mol. Med. Rep. 20(3), 2823–2831 (2019).
   PubMed Web of Science ®Google Scholar
• Li X, Tsuji M, Schneck J, Webb TJ. Generation of Human iNKT Cell Lines. Bio. Protoc. 3(6), e418 (2013).
   PubMedGoogle Scholar
• Ingegnere T, Mariotti FR, Pelosi A et al. Human CAR NK cells: a new non-viral method allowing high efficient transfection and strong tumor cell killing. Front Immunol. 10, 957 (2019).
   PubMed Web of Science ®Google Scholar
• Maenhoudt N, Vankelecom H. Protocol for establishing organoids from human ovarian cancer biopsies. STAR Protoc. 2(2), 100429 (2021).
   PubMedGoogle Scholar
• Zhang R, Siu MKY, Ngan HYS, Chan KKL. Molecular biomarkers for the early detection of ovarian cancer. Int. J. Mol. Sci. 23(19), 12041 (2022).
   PubMed Web of Science ®Google Scholar
• Ji DD, Wu MX, Ding SN. Photonic crystal barcodes assembled from dendritic silica nanoparticles for the multiplex immunoassays of ovarian cancer biomarkers. Anal. Methods 14(3), 298–305 (2022).
   PubMed Web of Science ®Google Scholar
• Mimpen M, Rolf L, Muris AH et al. NK/T cell ratios associate with interleukin-2 receptor alpha chain expression and shedding in multiple sclerosis. J. Neuroimmunol. 353, 577499 (2021).
   PubMed Web of Science ®Google Scholar
• Johnson CDL, Zale NE, Frary ED, Lomakin JA. Feeder-cell-free and serum-free expansion of natural killer cells using cloudz microspheres, G-Rex6M, and human platelet lysate. Front Immunol. 13, 803380 (2022).
   PubMed Web of Science ®Google Scholar
• Becker PS, Suck G, Nowakowska P et al. Selection and expansion of natural killer cells for NK cell-based immunotherapy. Cancer Immunol. Immunother. 65(4), 477–484 (2016).
   PubMed Web of Science ®Google Scholar
• Klingemann H. Challenges of cancer therapy with natural killer cells. Cytotherapy 17(3), 245–249 (2015).
   PubMed Web of Science ®Google Scholar
• Cantoni C, Wurzer H, Thomas C, Vitale M. Escape of tumor cells from the NK cell cytotoxic activity. J. Leukoc. Biol. 108(4), 1339–1360 (2020).
   PubMed Web of Science ®Google Scholar
• Lehmann J, Caduff N, Krzywinska E et al. Escape from NK cell tumor surveillance by NGFR-induced lipid remodeling in melanoma. Sci. Adv. 9(2), eadc8825 (2023).
   PubMed Web of Science ®Google Scholar